Abbott: Clean, Accessible Water for a Healthy Future

Abbott

Water sustains life, health, and ecosystems. It's a vital resource for a global healthcare company striving to help people around the world live healthier, fuller lives.

But water availability and quality are facing global challenges due to factors like population growth, climate change, industrial expansion, and intensive agriculture. The United Nations predicts a 40% global shortfall of water by 2030 - and it warns that 2.3 billion people around the world don't have adequate access to water and soap for handwashing, critical for a healthy existence.

Water is critical in our efforts to innovate life-changing healthcare technologies. We are committed to efficiently and responsibly managing our water use wherever we work to minimize our impact on local resources.

Our approach is four-fold: improve water efficiency, manage water discharges, apply key water-management practices companywide, and educate our employees and suppliers about the importance of responsible water use.

As part of our 2030 Sustainability Plan, we committed to:

  • Achieve water stewardship certification at all high-water-impact manufacturing sites in water-stressed areas.
  • Implement accredited water stewardship management practices in more than 75% of all manufacturing sites operating in water-stressed areas.
  • Work with 50 key suppliers in high water-stressed areas to reduce water quality and quantity risks to Abbott and the community.

We've been focused on responsible water usage for decades and these goals are meant to target our efforts at making the most impact. We're proud to be making progress and on track to meet these goals by 2030.

Assessing the Environment

Each year, we perform a mapping process to understand where the water we use comes from, how it's treated and discharged and the impact our operations have on local supply. During this process, Abbott has identified 24 of our manufacturing sites globally that operate in water-stressed areas.

In response, we've become a member of the Alliance for Water Stewardship (AWS), a global collaboration of businesses and NGOs that contribute to the sustainability of local water resources. Two Abbott sites in high-water-impact and water-stressed areas - in California and Spain - received important AWS certification in 2022 and four others in California, Chile, India, and Singapore are working toward certification. Five more sites are slated to pursue future certification during the plan's course.

Thirteen additional Abbott manufacturing sites in areas considered water-stressed but not in high water impact also started implementing water stewardship practices last year.

Partnering for Greater Impact

It will take everyone working together to make the biggest impact in water stewardship. That's why partnership is part of our approach and why, for example, we engage our suppliers in high water-stressed areas to work with us to reduce risks to water quality and quantity. So far, we've engaged 26 Abbott suppliers from water-stressed locations to identify water management opportunities and have piloted more robust partnerships with five key suppliers to reduce our shared-water impacts.

As part of our AWS certification efforts, Abbott also works with local communities to solve shared water challenges because successful water management accounts for local water and biodiversity needs. This means identifying opportunities to have an impact - and acting. For example:

  • Our AWS-certified site in Spain donates empty, bulk containers to a local reforestation nonprofit group, supporting irrigation of trees and recycling of the containers.
  • In California our AWS-certified site partners with a waste disposal company to provide compost to a local winery to improve soil conditions.

Looking Forward

We're committed to maintaining sustainable, efficient, and comprehensive water management programs and finding new approaches to upgrade our existing sites and processes to make the most positive impacts on water quality and supply in areas where we operate globally.

As we pursue the goals in our 2030 plan, we'll continue to map our water use and track trends globally, as well as look for new ways to engage our employees and partners in our water stewardship efforts.

See below resources to find out more about Abbott's efforts to manage water usage efficiently and responsibly.

Abbott, Wednesday, March 22, 2023, Press release picture

View additional multimedia and more ESG storytelling from Abbott on 3blmedia.com.

Contact Info:
Spokesperson: Abbott
Website: https://www.3blmedia.com/profiles/abbott
Email: info@3blmedia.com

SOURCE: Abbott



View source version on accesswire.com:
https://www.accesswire.com/745279/Abbott-Clean-Accessible-Water-for-a-Healthy-Future

News Provided by ACCESSWIRE via QuoteMedia

ABT
The Conversation (0)
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies (TSXV:ZCT)

Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company is preparing to conduct a full preclinical study of its final human-use device in up to 24 additional sheep.

The company has successfully completed a two sheep protocol pilot trial in November 2023, and is now preparing to expand the study. The ZC-1-A device was confirmed as 100% safe for use, with findings concluded from the Shamir Medical Center.

Keep reading...Show less

Thermo Fisher Scientific to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. (EST).

You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 30, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, January 30, 2025, and will hold a conference call on the same day at 8:30 a.m. EST.

During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 706921. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com . The earnings press release and related information can also be found in that section of our website under the heading "Financials". A replay of the call will be available under "News, Events & Presentations" through Friday, February 14, 2025.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×